Numerai’s Xeris Biopharma Holdings XERS Stock Holding History

Numerai’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,148	Closed	-$135K	–	910
2025 Q4	$135K	Sell	17,148 -1,359	-7%	-$10.7K	0.02%	593
2025 Q3	$151K	Buy	+18,507	New	+$123K	0.02%	526

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Numerai's XERS Position: Q1 2026 in Review

Numerai sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 17,148 shares — an estimated $135K sold.

Numerai first reported a position in XERS in Q3 2025 and held it in 2 quarters. The position peaked at $151K in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Numerai reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
Numerai sold 17,148 Xeris Biopharma Holdings shares in Q1 2026, an estimated $135K.
Numerai first reported a position in Xeris Biopharma Holdings in Q3 2025 and held it in 2 quarters.
Numerai's Xeris Biopharma Holdings position peaked at $151K in Q3 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Numerai's 13F filing for Q1 2026, filed 15 May 2026.